Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Shares of Eli Lilly ( LLY -2.37%) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker with a market cap of over $500 billion is in a sharp drawdown due to ...

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

The iPhone maker's shares [rallied for a second day]( ...

Eli Lilly (LLY) has recently launched SenderraCare+, a digital solution paired with its biologic treatment EBGLYSS, and announced positive outcomes from a Phase 3 trial for the weight management drug ...